Nuvation Bio Inc. Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened

• Nuvation Bio Inc. (NUVB) filed a Form 8-K on August 6, 2026 (Item 2.02) announcing its financial results for the quarter ended June 30, 2026.
• The company furnished a press release as Exhibit 99.1 to the 8-K; the filing notes the press release and related information are furnished (not “filed”) under the Securities Exchange Act.

Key Details

• Filing date: August 6, 2026.
• Reporting item: Item 2.02 — Results of Operations and Financial Condition.
• Disclosure format: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Legal note: Information in the Form 8-K and Exhibit 99.1 is furnished and therefore is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• This 8-K signals that Nuvation Bio has released its latest quarterly results — investors should review the press release (Exhibit 99.1) for revenue, profit/loss, cash position, and any forward-looking commentary or guidance.
• Because the press release is furnished (not filed), it generally isn’t incorporated by reference into other filings; investors should treat the press release as the primary source for the quarter’s reported financial details.
• If you follow Nuvation Bio, check the full press release and subsequent filings (e.g., Form 10-Q) for detailed financial metrics and any management discussion that could affect the stock.